Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 12.39 is in line with its 5-year average of 11.82, around the middle of its 5-year range (4.24–20.87).
As of the fiscal period ended Tuesday, June 30, 2026. 45.98% above its 12-month average of 8.49.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.39.
CURRENT RATIO
12.39
CURRENT RATIO AVG TTM
8.49
CURRENT RATIO AVG 3Y
8.06
CURRENT RATIO AVG 5Y
11.82
CURRENT RATIO AVG 10Y
10.53
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+45.98%
CURRENT VS 3Y AVG
+53.73%
CURRENT VS 5Y AVG
+4.83%
CURRENT VS 10Y AVG
+17.59%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+230.31%
vs the sector median at left
Ovid Therapeutics Inc.
Market Cap
$448.87M
Current Ratio
12.39
TTM Avg
8.49
3Y Avg
8.06
5Y Avg
11.82
Market Cap
$446.69M
Current Ratio
6.72
TTM Avg
10.04
3Y Avg
13.74
5Y Avg
16.43
Market Cap
$443.94M
Current Ratio
7.35
TTM Avg
8.39
3Y Avg
5.06
5Y Avg
6.73
Market Cap
$435.88M
Current Ratio
13.99
TTM Avg
3.82
3Y Avg
4.25
5Y Avg
5.96
Market Cap
$434.56M
Current Ratio
22.29
TTM Avg
19.64
3Y Avg
11.19
5Y Avg
11.30
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | $448.87M | 12.39 | 8.49 | 8.06 | 11.82 |
| NeuroPace, Inc. (NPCE)vs › | $445.95M | 4.94 | 5.33 | 6.32 | 7.54 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $446.69M | 6.72 | 10.04 | 13.74 | 16.43 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $443.94M | 7.35 | 8.39 | 5.06 | 6.73 |
| NRC Health (NRC)vs › | $456.59M | 0.65 | 0.55 | 0.77 | 1.10 |
| Assembly Biosciences, Inc. (ASMB)vs › | $435.88M | 13.99 | 3.82 | 4.25 | 5.96 |
| Tectonic Therapeutic, Inc. (TECX)vs › | $434.56M | 22.29 | 19.64 | 11.19 | 11.30 |
| NeoGenomics, Inc. (NEO)vs › | $431.42M | 3.60 | 3.12 | 4.79 | 5.52 |
| Editas Medicine, Inc. (EDIT)vs › | $430.46M | 3.19 | 3.65 | 4.66 | 6.11 |
| Sight Sciences, Inc. (SGHT)vs › | $469.56M | 4.95 | 9.63 | 11.08 | 12.07 |
Current Ratio
12.39
Quick Ratio
12.39
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 12.39 |
| 2026-03-31 | 10.17 |
| 2025-12-31 | 10.91 |
| 2025-09-30 | 4.24 |
| 2025-06-30 | 4.72 |
| 2025-03-31 | 4.93 |
| 2024-12-31 | 5.32 |
| 2024-09-30 | 5.66 |
| 2024-06-30 | 5.73 |
| 2024-03-31 | 10.47 |
| 2023-12-31 | 9.55 |
| 2023-09-30 | 10.59 |
| 2023-06-30 | 10.07 |
| 2023-03-31 | 17.78 |
| 2022-12-31 | 18.79 |
| 2022-09-30 | 20.87 |
| 2022-06-30 | 16.94 |
| 2022-03-31 | 16.63 |
| 2021-12-31 | 12.87 |
| 2021-09-30 | 20.37 |
| 2021-06-30 | 19.12 |
| 2021-03-31 | 14.48 |
| 2020-12-31 | 3.39 |
| 2020-09-30 | 5.03 |
| 2020-06-30 | 3.02 |
| 2020-03-31 | 6.08 |
| 2019-12-31 | 7.58 |
| 2019-09-30 | 3.78 |
| 2019-06-30 | 5.84 |
| 2019-03-31 | 7.78 |
| 2018-12-31 | 5.01 |
| 2018-09-30 | 5.30 |
| 2018-06-30 | 8.70 |
| 2018-03-31 | 11.50 |
| 2017-12-31 | 14.71 |
| 2017-09-30 | 21.02 |
| 2017-06-30 | 15.19 |
| 2017-03-31 | 9.56 |
| 2016-12-31 | 14.04 |
| 2016-09-30 | 21.76 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 30.44 |
